Estrella Immunopharma, Inc. (ESLA): Nasdaq/NYSE listing notice — TradeUP Acquisition Corp. receives Nasdaq delisting notice for MVLS below $35M

Estrella Immunopharma, Inc.

Nasdaq notified TradeUP on April 3, 2023 that its Market Value of Listed Securities (MVLS) was below $35M for 30 consecutive business days.
The deficiency is under Nasdaq Listing Rule 5550(b)(2); the notice does not trigger immediate delisting.
Company has 180 days, until October 2, 2023, to regain compliance by achieving MVLS of at least $35M for 10 consecutive business days.
Failure to cure by the deadline will result in a delisting notice; the company may appeal any such determination.
TradeUP is evaluating options to regain compliance, but there is no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

April 3, 2023, TradeUP Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the

View on SEC.gov

Browse all listing & compliance notices →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001575872-23-000519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.